SFI
APLS

Susquehanna Fundamental Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35,264
Closed -$1.16M – 1421
2021
Q3 		$1.16M Sell
35,264
-297
-0.8% -$16.7K 0.02% 807
2021
Q2 		$2.25M Sell
35,561
-3,700
-9% -$191K 0.04% 564
2021
Q1 		$1.69M Buy
39,261
+6,544
+20% +$310K 0.03% 704
2020
Q4 		$1.87M Buy
+32,717
New +$1.38M 0.03% 647

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Susquehanna Fundamental Investments's APLS Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Apellis Pharmaceuticals (APLS) in Q4 2021, closing a stake of 35,264 shares — an estimated $1.16M sold.

Susquehanna Fundamental Investments first reported a position in APLS in Q4 2020 and held it in 4 quarters. The position peaked at $2.25M in Q2 2021. 186 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Apellis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 35,264 Apellis Pharmaceuticals shares in Q4 2021, an estimated $1.16M.
  • Susquehanna Fundamental Investments first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Apellis Pharmaceuticals position peaked at $2.25M in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.